{"id":859469,"title":"Summary: NACI update on the recommended use of palivizumab to reduce complications of respiratory syncytial virus infection in infants, CCDR 48(7/8) - Canada.ca","sourceCode":"phac","sourceName":"Public Health Agency of Canada","language":"en","captureDate":"2026-02-16","captureTimestamp":"2026-02-16T05:53:30.725000+00:00","jobId":7,"originalUrl":"https://www.canada.ca/en/public-health/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2022-48/issue-7-8-july-august-2022/summary-national-advisory-committee-immunization-naci-statement-update-recommended-use-palivizumab-reduce-complications-respiratory-syncytial-virus-infection-infants.html","snippet":"National Advisory Committee on Immunization (NACI) statement update on the recommended use of palivizumab on complications of respiratory syncytial virus infection in infants Download this article as a PDF Published by: The Public Health Agency of Canada Issue: Volume 48-7/8,…","rawSnapshotUrl":"/api/snapshots/raw/859469","browseUrl":"https://replay.healtharchive.ca/job-7/20260216055330/https://www.canada.ca/en/public-health/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2022-48/issue-7-8-july-august-2022/summary-national-advisory-committee-immunization-naci-statement-update-recommended-use-palivizumab-reduce-complications-respiratory-syncytial-virus-infection-infants.html#ha_snapshot=859469","mimeType":"text/html","statusCode":200,"captureBackend":"playwright_warc","captureFidelity":"fallback"}